GelStat (OTCMKTS:GSAC) is a biotechnology company focused on the development, manufacturing and commercialization of advanced polymer-based hydrogel technologies for the medical and life sciences markets. The company’s core competencies lie in its proprietary formulations, which are designed to address critical needs in surgical hemostasis, wound care and interventional procedures. GelStat’s products leverage unique polymer cross-linking methods to deliver consistent performance, biocompatibility and ease of use for healthcare practitioners.
The company’s flagship product line includes surgical sealants and topical hemostatic agents that are used in a range of procedures from cardiovascular and orthopedic surgeries to minimally invasive interventions. These hydrogel-based formulations create an effective physical barrier at the site of application, helping to control bleeding and promote tissue healing without systemic side effects. GelStat also offers custom development services, partnering with medical device OEMs to integrate its gel technologies into catheters, implants and diagnostic platforms.
Headquartered in the United States, GelStat maintains manufacturing facilities compliant with current Good Manufacturing Practice (cGMP) standards and serves a global customer base, including hospitals, surgical centers and research institutions across North America, Europe and Asia-Pacific. The company works closely with strategic distribution partners and regulatory consultants to support product registrations and market access in key jurisdictions. Ongoing investments in R&D have enabled GelStat to expand its pipeline of next-generation hydrogels, targeting emerging applications such as endovascular embolization and advanced wound dressings.
Since its founding in 2005, GelStat has been guided by a leadership team with deep expertise in polymer chemistry, medical device regulation and clinical sales. The board of directors includes seasoned executives from the pharmaceutical and device sectors, while the management team is led by Chief Executive Officer Dr. Laura Reynolds, a biomedical engineer with more than two decades of experience in biomaterials research. Together, they are focused on driving commercialization efforts, forging collaborative alliances and delivering innovative solutions that improve patient outcomes.
AI Generated. May Contain Errors.
